NorthWest Biotherapeutics Inc (NWBO)

[KRISGO]

Mani, I agree with Lykiri’s perspective on this. If things are moving in the right direction, Northwest is likely using this time to focus on essential administrative steps. Given that they operate with a lean team, receiving approval around the time of ASCO could easily cause delays. According to their recent 10-K, they intend to act quickly on MHRA-related matters and already have partners lined up — they're simply waiting on approval. That positions them to move swiftly on the business front without needing to divert limited resources to ASCO. Besides, if approval does come through, the entire biotech community will be aware, whether or not they’re at ASCO. In my view, skipping ASCO at this point isn’t a concern, especially with the time pressures they’re facing.